Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Galapagos Buys Drug Firm, Extends Pact

January 8, 2007 | A version of this story appeared in Volume 85, Issue 2

Belgian drug discovery firm Galapagos will acquire the bone disease specialist ProSkelia from ProStrakan Group for about $16 million plus up to $19 million in future payments. Galapagos CEO Onno van de Stolpe says ProSkelia will join his firm's arthritis drug program to create "a leader in the discovery and development of small-molecule drugs to treat bone and joint disease." Separately, Galapagos' BioFocus DPI service division has extended a drug discovery collaboration with Amgen through 2008. BioFocus will provide biology, computational, and medicinal chemistry services to Amgen's discovery programs for up-front fees of $2.4 million and possible other payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.